Mastering Medicinal 91AV is back by popular demand for the fi fth year in a row. This year will kick-off with an executive overview of recent industry trends and concepts in medicinal chemistry from a strategic level. To follow, several new NDA approvals will be featured as chemistry case studies, from bench to the clinic, along with case presentations on several of the more aggressively pursued targets in the industry including: Kinase, HDAC's HCV, DPPIV, CCR5 and more. 91AV projects across multiple therapeutic areas including Cancer, Metabolic Diseases, CNS, with a particular look at Pain and Antinfectives will also be a feature this year. There will be some coverage of technologies and strategies driving more efficient medicinal chemistry including fragment-based screening, outsourcing activities and the drive toward more improved synthetic efficiency will be featured. Attend to learn more.
Explore
Membership
